Purpose: This two-part study comprised two descriptive, cross-sectional surveys to evaluate treatment satisfaction among patients with systemic lupus erythematosus (SLE) and their physicians from US clinical practices. The Lupus Plus Project (LPP; part one) involved belimumab-containing regimens; the Disease Specific Program (DSP; part two) included all treatments and was designed to build on the body of evidence from part one.
patient-reported satisfaction for patients receiving belimumab were patient-reported improvements in leisure activities since taking belimumab (odds ratio [OR] ¼ 4.66), physician-reported improvements in fatigue (OR ¼ 3.72), patient-reported improvements in general symptoms (OR ¼ 3.02), and pain/achiness (OR ¼ 2.71). Physician satisfaction was associated with clinical outcome such as improvements in pain/achiness (OR ¼ 6.16), fatigue (OR ¼ 3.76), and patient-reported satisfaction with treatment frequency (OR ¼ 3.91). In patients receiving other SLE treatments, dosing frequency of current treatment (OR ¼ 3.64) and a reduction in fatigue severity (OR ¼ 3.61) were most strongly associated with patient-reported satisfaction; physician satisfaction was most strongly associated with a reduction in fatigue (OR ¼ 6.22) and current remission status (OR ¼ 6.05).
Implications: When considering SLE treatment satisfaction patients tend to consider impact on daily functioning, whereas physicians take into account a wider range of clinical outcomes; however, both strongly consider improvements in fatigue. These surveys provide insights into treatment satisfaction among prescribers and patients with SLE. GSK-Clin-icalStudyRegister.com identifiers: GSK study 202146 [ HO 15-15509] 
INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse manifestations, characterized by periods of remission and flare. 1, 2 There is no cure for SLE; however, several classes of drugs are used to manage the disease, including corticosteroid (CS), antimalarial (AM), and immunosuppressant (IS) agents and non-steroidal anti-inflammatory drugs (NSAIDs). 3 Belimumab is a human IgG1λ monoclonal antibody approved for the treatment of adult patients with active, autoantibody-positive SLE who are receiving standard SLE therapy (referred to as standard of care [SoC] ). The safety profile and efficacy of belimumab have been reported in two Phase III studies, Belimumab in Subjects with Systemic Lupus Erythematosus (BLISS)-52 and BLISS-76, in patients with autoantibody-positive, active SLE. 4, 5 An open-label, continuation study of the BLISS studies has reported an acceptable safety profile of belimumab for 5 years, 6 and a continuation study of a Phase II study reported that efficacy and tolerability outcomes were maintained up to 7 years. 7 Patient satisfaction has been shown to correlate with medication compliance and adherence, 8 both of which are challenging in chronic conditions such as SLE. 9 It is therefore worthwhile to investigate physician and patient satisfaction with belimumab, to further evaluate the real-world benefit of belimumab plus SoC.
This study reports data collected from the Adelphi Real World (ARW) Lupus Plus Project (LPP) and the Lupus Disease Specific Program (DSP) surveys. The LPP explored the use of belimumab from both the physician and patient perspective within US clinical practice. The DSP was a larger study that enrolled patients with SLE receiving any treatment. Thus, the DSP provided an opportunity to build on the body of evidence in patients receiving belimumab, generated by the LPP, and to contextualize the findings in relation to outcomes in patients receiving non-belimumab regimens.
METHODS

Study Design
This study reports data collected as part of the LPP and DSP. The LPP was a descriptive cross-sectional real-world survey of US rheumatologists and patients with SLE receiving belimumab alone or in combination with standard SLE therapy, which was conducted for the first time. After the LPP, a descriptive crosssectional survey of US rheumatologists and their patients with SLE (the DSP) was performed. DSP surveys use validated methods to generate data from clinical practice regarding treatment practices, resource use, and quality of life. 10, 11 The Lupus DSP is conducted at regular intervals (previously in 2010 and 2013), and it also collected data from nephrologists and their patients with lupus nephritis; here, we focus on rheumatologists and patients with SLE. The LPP used specific sections of the previous Lupus DSP survey, and both surveys were developed by ARW independent of GlaxoSmithKline (GSK), using the Adelphi Disease Specific Programme method. 11 The LPP survey comprised two paper questionnaires: a patient record form (PRF) completed by the physician and a patient self-completion questionnaire (PSC). The DSP survey consisted of four parts: physician interviews conducted face to face with participating physicians, a PRF completed by the physician after a patient consultation, and a PSC. A workload form was also completed in both surveys by the physicians to indicate their total SLE patient workload.
GSK sponsored an analysis of the anonymized data and prospectively added questions pertinent to the use of belimumab and/or current treatment and the management of SLE. The LPP survey was concluded 5 months before the DSP.
The number of physicians and patients who were satisfied with treatment was assessed. Satisfaction according to various factors was assessed, including demographic and disease characteristics and status and quality of life outcomes. Factors that were associated with satisfaction were identified. Tolerability was not assessed in this study; however, treatmentrelated adverse events recorded in the PRF and PSC were reported to GSK.
Study Population
For both arms of the study, eligible patients had a current, confirmed SLE diagnosis, were receiving marketed treatment for SLE (a small number of patients were also receiving rituximab), were ≥18 years of age, and were managed by a rheumatologist actively involved in the management of ≥4 (LPP) or ≥5 (DSP) patients with SLE per typical month. Board-certified rheumatologists who qualified as a practicing physician between 1971 and 2013 were recruited for screening from locations across the United States to ensure a geographically representative sample. In the LPP, all patients were currently receiving belimumab and had been receiving it for ≥3 months.
Study Objectives
The LPP explored the outcomes in patients receiving belimumab plus SoC from both the physician and patient perspective within US clinical practice. The objective was to describe the degree of satisfaction with their current treatment, scored on a 7-point verbal scale from "very dissatisfied" to "very satisfied" in patients who had taken belimumab in addition to SoC for at least 3 months and to explore factors associated with patient satisfaction.
The DSP built on the body of evidence generated by the LPP and was used to contextualize these results in relation to outcomes observed in the broader lupus population, who were not currently receiving belimumab. The objective was to describe the degree of physician-and patient-reported treatment satisfaction.
Data Analyses
All objectives were prespecified in a reporting and analysis plan. Descriptive analyses were used to describe the baseline characteristics of physicians and patients. Continuous variables were described using the frequency, mean, and range. Categorical variables were described using the number and percentage of physicians or patients in each category. Physicians and patients were not required to respond to all questions; missing data were removed from the variable total, and results were calculated using the total completion base for each question.
Bivariate testing assessed differences in satisfaction for key subgroups. Tests used were dependent on the variable; the Chen-Shapiro test was used to define normal distribution. Analysis of variance with post hoc Bonferroni-corrected t tests was used for continuous and normally distributed variables. Kruskal-Wallis testing with post hoc Bonferroni-corrected Mann-Whitney tests were used when the outcome variable was either continuous and not normally distributed, or categorical and ordinal. χ 2 testing with post hoc Bonferroni-corrected χ 2 and Fisher's exact tests (when appropriate) was used for categorical outcome variables.
To investigate factors associated with physician and patient satisfaction with belimumab, a multivariate approach was used. Initially, a list of potential covariates was determined (from 4500 variables available in the DSP) from disease understanding and the potential impact of those covariates on satisfaction ( Table I) . For the given sample size, the list was deemed too large; therefore, a backward stepwise approach was then used to reduce the number of variables in the final model. A standard backward step-wise approach starts with the full list, runs a regression, and removes the variable with the highest P value (assuming that P value is higher than the set significance level [usually 0.05]). This is repeated with the updated list, and then each of the variables that have been removed are added in turn to see if they are then below the set significance level. The attempted removal and addition of variables is repeated until no more variables can be removed or added. In a standard approach, if there are some missing values within the full covariate list of variables, the final model only contains observations with valid values for all variables within the full covariate list (and not just the variables in the final model). Therefore, to potentially increase the number of observations in the final model, we used an amended version of the standard approach. The standard approach was run with the significance level set at 0.2. The final set of variables from this phase were entered into another standard backward step-wise with the significance level set at 0.1. This was finally repeated with the significance level set at 0.05. This approach has the effect of including more observations at each phase if the reduced variable list has fewer missing values; hence, the final model from the final phase may have fewer missing values than if the standard approach was used. This means that variables removed during a previous phase cannot be re-introduced during a subsequent phase; given that the full list of covariates in this analysis was not large and that the covariates were selected with good rationale, this was not expected to be detrimental.
Post-estimation tests were performed to test for multicollinearity; variance inflation factors (VIFs) were not considerably larger than 1 for either the physician or patient model and no VIF was in excess of 10, indicating that there was no significant multicollinearity in either of the final models. Standard errors were adjusted for the intraclass correlation between patients consulting with the same physician. The level of concordance between the physician-and patient-reported satisfaction was investigated using descriptive and Cohen's κ analyses. For some analyses, including the bivariate and multivariate analyses, satisfaction was stratified as unsatisfied (including "very dissatisfied," "dissatisfied," "somewhat dissatisfied," and "neither satisfied nor dissatisfied" responses), somewhat satisfied, and satisfied (including "satisfied" and "very satisfied" responses).
Data were received by ARW in a format read by QPSMR's Reflect software (QPSMR Ltd, Oxfordshire, UK). All statistical analysis was performed using Stata 13.1 (Stata Corp, College Station, TX) or higher. No physician-or patient-identifiable data were collected. An institutional review board waiver was obtained for both the LPP and DSP.
RESULTS
Study Participants
The LPP collected data from January 2015 to March 2015. Rheumatologists (n ¼ 70) from 20 sites across the United States participated; a total of 376 sample PRFs and 270 PSCs were provided for patients with SLE currently prescribed belimumab plus SoC. Commonly reported SoC included AM (55.9%, 210/ 376), CS (44.7%, 168/376), and IS (33.2%, 125/376) agents. The mean time since SLE diagnosis was just 47 years (88.7 months; range, 5-480 months) and the mean time on belimumab was 12.6 months (range, 3-72 months), with 21.4% of patients (80/373) having received belimumab for 3 to 6 months and 78.6% (293/373) for 46 months; 1.1% of patients (4/376) were deemed to have mild disease before (Table II) . The most common organ involvement was combined musculoskeletal and mucocutaneous (40.1%); 37.1% of patients had musculoskeletal involvement only, 3.2% had mucocutaneous involvement only, and 2.0% had renal involvement only. The majority of patients (55.1%, 277/502) were white/Caucasian and 24.1% (121/502) were African American. The patients' mean age was 43.5 (14.24) years. Most patients were women (87.1%, 437/502).
Treatment Satisfaction Patients Receiving Belimumab
In the LPP, 263 patients taking belimumab plus SoC responded to the satisfaction questions. The majority (86.3% [227/263]) of these patients and their physicians (82.9% [311/375]) responded positively (at least somewhat satisfied) when asked about their satisfaction with current treatment; 28.5% of patients (75/263) and 21.6% of physicians (81/375) were very satisfied with belimumab-containing regimens ( Figure 1A) . In bivariate analyses, patients who had been receiving belimumab for 3 to 6 months reported lower levels of satisfaction (41.4% [24/58] satisfied [responded satisfied or very satisfied]) than patients who had been receiving belimumab for 6 to 12 months (64.3% [72/112] satisfied) and (Figure 2A) . Physicianreported improvements in fatigue (OR ¼ 3.72; 95% CI, 1.77-7.79), patient-reported improvements in general symptoms (OR ¼ 3.02; 95% CI, 1.15-7.94) and pain/achiness (OR ¼ 2.71; 95% CI, 1.12-6.52) were also strong drivers of patient satisfaction. Satisfaction with administration time and frequency of treatment were also drivers of satisfaction (Figure 2A) . In exploratory analyses, 50.8% of patients (134/264) reported that they would prefer to self-administer injections at home compared with 20.5% (54/264) who would prefer intravenous (IV) injection at a clinic; 28.8% (76/264) stated that they had no preference. Employment rates were higher among patients who would prefer to self-administer injections at home than patients who would prefer injection at a clinic (79.3% versus 44.4%, respectively).
Physician satisfaction with belimumab-containing regimens was associated with clinical outcomes, such as improvements in patient-reported pain/achiness (OR ¼ 6.16; 95% CI, 2.20-17.24) and physicianreported fatigue (OR ¼ 3.76; 95% CI, 1.90-7.40), but also with higher patient-reported satisfaction with treatment frequency (OR ¼ 3.91; 95% CI, 2.02-7.56) and the number of physician-reported consultations in the previous 12 months (OR ¼ 1.18; 95% CI, 1.03-1.36).
In the LPP, factors that negatively affected overall patient satisfaction included greater disease severity before belimumab initiation (OR ¼ 0.36; 95% CI, 0.14-092) and concomitant use of IS therapy (OR ¼ 0.40; 95% CI, 0.19-0.84).
Physician dissatisfaction was driven by a greater number of factors that for patients; however, these still predominantly relate to clinical outcomes. The number of flares in the past 12 months (OR ¼ 0.75; 95% CI, 0.63-0.91), concomitant IS use (OR ¼ 0.46; 95% CI, 0.26-0.83), a greater degree of current severity (OR ¼ 0.29; 95% CI, 0.13-0.63), and a deterioration in disease state (OR ¼ 0.13; 95% CI, 0.06-0.26) were all clinical outcomes associated with physician dissatisfaction (Figure 2A) .
In bivariate analyses, no association between patient satisfaction with belimumab and patient demographic factors (age, sex, ethnicity, or employment status) was found; however, a number of clinical variables were associated. A significant association (P o 0.0001, all groups) was identified between overall patient satisfaction with belimumab and physician-reported current disease severity, current deterioration in disease state change in disease severity since belimumab initiation, change in flare frequency, and change in flare severity (Table III ). In addition, improvements in general symptoms, fatigue, and pain/achiness were identified as factors that affected patient satisfaction with belimumab in bivariate analyses (data not shown), which is in agreement with the multivariate analysis findings. Improvements in leisure activities was a significant factor in bivariate analyses, as in multivariate analyses. Additional daily functioning outcomes that were significant in the bivariate analyses were improvements in work, activities of daily living, and personal relationships (Table III) . ⁎ Satisfaction was stratified as unsatisfied (including "very dissatisfied," "dissatisfied," "somewhat dissatisfied," and 'neither satisfied nor dissatisfied" responses), somewhat satisfied and satisfied (including "satisfied" and "very satisfied" responses). † Difference in satisfaction across the different clinical and patient functioning outcomes. ‡ Since initiating current treatment.
Odds ratio (95% confidence interval) Factor associated with patient satisfaction (n=262)
Patients Receiving Non-Belimumab Treatments
In the DSP, 250 patients with non-belimumab treatment regimens responded to the satisfaction questions. The majority of these patients (78.4% [196/250]) and their physicians (74.3% [326/439]) responded positively (at least somewhat satisfied) when asked about their satisfaction with current treatment; 22.8% of patients (57/250) and 24.4% of physicians (107/439) were very satisfied with nonbelimumab treatment ( Figure 1B) . The factors most strongly associated with patient-reported satisfaction (satisfied and very satisfied) were dosing frequency of current treatment (OR ¼ 3.64; 95% CI, 1.85-7.16) and reduction in fatigue severity since starting current treatment (OR ¼ 3.61; 95% CI, 1.85-7.05) ( Figure 2B) . The factors most strongly associated with physician-reported satisfaction were the patient's current physician-reported remission status (OR ¼ 6.05; 95% CI, 2.91-12.56) and physicianreported changes in fatigue (OR ¼ 6.22; 95% CI, 2.93-13.23). Whether a patient received AM monotherapy (OR ¼ 4.84; 1.52-15.40), their satisfaction with the frequency requirement of current treatment (OR ¼ 2.76; 1.14-6.70), and improvement in tasks that require focus and concentration (OR ¼ 2.43; 1.07-5.50) were also seen as significant drivers of physician satisfaction with current treatment.
In the DSP, greater severity (physician-reported) before treatment (OR ¼ 0.20; 95% CI, 0.09-0.48) and current treatment involving AM plus CS plus IM combinations (OR ¼ 0.39; 95% CI, 0.16-0.97) were seen as drivers of patient dissatisfaction ( Figure 2B) . Physician dissatisfaction with current treatment was driven by increased health care professional consultations (OR ¼ 0.87; 95% CI, 0.76-0.99) and physician-reported current deterioration in disease state (OR ¼ 0.20; 95% CI, 0.07-0.54).
A high degree of concordance was seen between significant factors observed in the bivariate and multivariate analyses. Significant clinical factors in the bivariate analysis included physician-reported current disease severity, change in disease severity since initiation of current treatment (Table III) , current disease state, number of organs affected, and current disease remission. Improvements in general symptoms and fatigue since current treatment initiation were also significantly associated with increased satisfaction among both physicians and patients (data not shown). Similarly, significant associations were noted between physician-and patient-reported satisfaction and multiple aspects of disease flaring, including current flare status, flare frequency (Table III) , and flare duration. Improvements in activities of daily living were significant factors in patients who were not receiving belimumab, but improvements in leisure activities, work, and personal relationships were not significant (Table III) .
Concurrent Use of CS Agents
Of those non-belimumab patients who reported the use of concurrent CS agents in the DSP and responded regarding their satisfaction with their current treatment, 28.1% (41/146) were unsatisfied (P ¼ 0.0019, all groups). Physicians reported that the majority of patients (belimumab, 69.6% [188/ 270]); non-belimumab, 70.2% [203/289]) were able to reduce their CS use since treatment initiation. Also in the LPP, both physician-and patientreported satisfaction were positively associated with reduced CS use in patients receiving belimumabcontaining regimens (P o 0.0001 and P ¼ 0.0141, respectively). In the DSP study, there was no significant association between a reduction in CS use and patient satisfaction with current non-belimumab treatment (P ¼ 0.0914), although a significant association with physician-reported satisfaction was seen (P o 0.0001).
Concordance Between Physician and Patient Satisfaction
The complete agreement rate between patient and physician satisfaction was 48% for belimumab-including regimens and 44% for non-belimumab treatments (κ ¼ 0.45 for both; Table IV) , with the highest concordance rates occurring when both the physician and patient were satisfied (belimumab, 17%; non-belimumab, 19%) or very satisfied (belimumab, 17%; non-belimumab, 14%). When stratified as satisfied (including satisfied and very satisfied responses), somewhat satisfied, and dissatisfied (including very dissatisfied, dissatisfied, somewhat dissatisfied, and neither satisfied nor dissatisfied responses), complete agreement was 68% (κ ¼ 0.45) for belimumab-including regimens and 63% (κ ¼ 0.47) with non-belimumab treatments.
DISCUSSION
These studies have evaluated physician and patient satisfaction with SLE treatment in the real-world setting and have identified factors that are associated with treatment satisfaction. Most patients and physicians were satisfied with their current treatment for SLE; nevertheless,~20% to 30% of patients and physicians were unsatisfied, which suggests there is still need for improvement. For both patients and physicians, improvements in clinical outcomes were associated with greater treatment satisfaction. However, consideration should be given to the humanistic focus of patient treatment satisfaction: although patients are more likely to consider primarily the impact of their treatment on daily functioning, physicians take into account a greater number of clinical outcomes when assessing their satisfaction/dissatisfaction with treatment. Concordance between physician and patient satisfaction was greatest among patients who were satisfied or very satisfied with their treatment. The level of physician and patient concordance suggests there is a need for improved communication between the two, particularly among dissatisfied patients, and it suggests that a more patient-centric approach to treatment is required.
In terms of age, sex, and ethnicity, the demographic profile of the patients participating in these studies were consistent with those of other belimumab studies 4, 5, 7, 12 and a previous survey of physicians and patients with SLE that investigated treatment burden. 13 According to physician assessment, in both studies most patients had moderate or severe disease and deteriorating or unstable disease before treatment initiation. In the LPP, 82.9% of physicians and 86.3% of patients were at least somewhat satisfied with belimumab-containing regimens. In the DSP, among patients with non-belimumab treatment regimens, these percentages were 78.4% and 74.3%, respectively. However, it should be noted that, although no formal statistical comparison was performed, the results suggest that patients who initiated belimumab treatment had more severe disease than patients receiving non-belimumab treatment regimens. Achieving treatment satisfaction in such a patient population may have been more unlikely. Furthermore, in the LPP, greater disease severity before belimumab initiation and concomitant use of IS therapy (both factors that can be considered a proxy for the patient's current severity), negatively affected patient satisfaction, suggesting that patient dissatisfaction is strongly driven by the patient's current disease state. These results suggest that belimumab was prescribed to patients whose condition was not sufficiently controlled by conventional SLE medications. Belimumab is indicated in patients with active autoantibody-positive SLE who are receiving SoC; for patients whose disease is not adequately managed by SoC alone, belimumab represents an additional treatment option. Some dissatisfaction was apparent in patients, and this depended on the type of treatment they received. Patients who received belimumab reported improvements in leisure activities and improvement in general symptoms, pain/achiness, and fatigue among the key drivers of satisfaction. Patients who did not receive belimumab reported frequency of dosing and improved fatigue to be among the key drivers of satisfaction. Given the tendency of patients to consider humanistic factors in determining treatment satisfaction, addition of belimumab to SoC may be considered for patients who are dissatisfied with SoC.
In both studies, frequency of administration was a driver of patient satisfaction. In the LPP, 50.8% of patients stated they would prefer to self-administer their injectable SLE medications at home rather than receive an IV injection at a clinic; the desire for home administration was greater among employed patients than among unemployed patients. These results suggest that the convenience and flexibility of treatment administration are important factors in patient treatment satisfaction. Initial trials of self-administered belimumab in healthy volunteers using an autoinjector device or prefilled syringe 14 and in patients with SLE using an autoinjector 15 have reported high levels of satisfaction with the belimumab autoinjector and a preference for subcutaneous administration to IV administration. 16 Subcutaneous administration of belimumab in patients with SLE has been further studied in a Phase III, randomized, double-blind, placebo-controlled trial to evaluate efficacy and tolerability after self-administration using the prefilled syringe during 52 weeks. 17 Efficacy and safety profile results from this study were consistent with results of the pivotal BLISS IV trials. 4, 5 Although the data are from retrospective surveys not prospective clinical studies, the LPP and DSP provide further patient-and physician-reported realworld data to complement the previously reported clinical benefits of belimumab. 4, 5 From the LPP findings on belimumab-containing regimens, we wished to see how the data compared with data from patients and physicians regarding non-belimumab treatment. The LPP and DSP provide valuable insights into the real-world effectiveness of treatment with or without belimumab, while also assessing the attitudes, behaviors, and satisfaction of prescribers and patients.
As with any survey or questionnaire, the patient may be limited by the available response options, which may lead to bias. Limitations of the surveys include that the samples were taken from patients actively consulting with physicians; therefore, they represent a subset of the whole lupus population; because the surveys were cross-sectional, patients seeing their physicians less frequently were less likely to be sampled. Limitations of the LPP include that the inclusion criteria required rheumatologists to be relatively high prescribers of belimumab, to ensure the patient recruitment was as streamlined as possible. Those sampled may not be representative of all rheumatologists who prescribe belimumab. Most patients who participated in the LPP study had received belimumab for at least 6 months; this may have resulted in selection of patients who were more satisfied with and were demonstrating a response to belimumab, because patients who had not responded to belimumab within this time frame are more likely to have ceased using the treatment. Consequently, the LPP sample may not be wholly representative of newly prescribed users. Because belimumab is indicated in patients with active autoantibody-positive SLE who are receiving SoC, it is not surprising that the belimumab-treated population would have more severe disease than the non-belimumab population. Because the patient populations in the LPP and DSP are not the same, the results of the two surveys cannot be directly compared.
The results of these studies point to key features influencing patient and physician satisfaction with SLE treatment. Key differences were apparent in terms of drivers of satisfaction in patients who were receiving belimumab compared with their physicians. The impact of improved patient functioning (improved ability to engage in leisure activities) was strongly associated with patient satisfaction, and greater consideration of clinical factors (eg, number of flares and current severity) were more strongly associated with physician satisfaction. A moderate level of concordance between physician-and patient-reported satisfaction was observed. Enhanced physician-patient discussion regarding factors associated with satisfaction will optimize the use of belimumab and will improve levels of concordance.
Historically, the management of autoimmune diseases has been largely physician centric, with limited emphasis on the patient's perception of his or her own condition and targets for treatment. Understanding the patient experience of SLE treatment offers insights into how physicians can better understand their patients' needs. The real-world findings from the LPP and DSP may be used to further facilitate physician-patient discussions regarding SLE management and may support physicians and patients in achieving optimal clinical outcomes in SLE.
